Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Groupama Asset Managment

Groupama Asset Managment increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 916,060 shares of the company's stock after purchasing an additional 36,084 shares during the period. Groupama Asset Managment owned approximately 0.58% of Ionis Pharmaceuticals worth $367,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IONS. Vanguard Personalized Indexing Management LLC lifted its position in Ionis Pharmaceuticals by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company's stock valued at $363,000 after purchasing an additional 261 shares during the period. Nicollet Investment Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company's stock worth $817,000 after buying an additional 294 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company's stock worth $399,000 after acquiring an additional 300 shares during the period. GAMMA Investing LLC increased its position in Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock valued at $27,000 after acquiring an additional 303 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its holdings in Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock valued at $43,000 after acquiring an additional 314 shares during the period. 93.86% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ IONS traded down $0.32 during mid-day trading on Tuesday, reaching $38.26. The company had a trading volume of 1,042,080 shares, compared to its average volume of 1,334,823. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of -15.68 and a beta of 0.35. Ionis Pharmaceuticals, Inc. has a 52 week low of $33.33 and a 52 week high of $54.44. The business's 50-day moving average is $37.59 and its 200-day moving average is $42.35. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86.

Insider Transactions at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 6,630 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the transaction, the chief executive officer now directly owns 167,393 shares of the company's stock, valued at approximately $6,369,303.65. The trade was a 3.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares in the company, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,877 shares of company stock valued at $299,578. 2.71% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IONS has been the topic of several recent research reports. Wells Fargo & Company lowered their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, November 7th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, November 12th. Royal Bank of Canada restated an "outperform" rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Finally, Piper Sandler lowered their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.